Search clinical trials for: proptosis

Total 11 results

Lassen Therapeutics Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

Eye Diseases | Endocrine System Diseases | Thyroid Eye Disease | Graves Ophthalmopathy | Orbital Diseases | Thyroid Associated Ophthalmopathy | Graves Orbitopathy | Proptosis

United States, United Kingdom, Spain
Sling Therapeutics, Inc.

Recruiting

A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

Eye Diseases | Endocrine System Diseases | Thyroid Diseases | Thyroid Eye Disease | Graves Ophthalmopathy | Exophthalmos | Orbital Diseases | Thyroid Associated Ophthalmopathy | Graves Orbitopathy | Proptosis | IGF1R | Hashimoto

United States
Medical University of Silesia

Recruiting

Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy

Graves Orbitopathy

Poland
Sling Therapeutics, Inc.

Active, not recruiting

A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) (LIDS)

Eye Diseases | Endocrine System Diseases | Thyroid Diseases | Thyroid Eye Disease | Graves Ophthalmopathy | Exophthalmos | Orbital Diseases | Thyroid Associated Ophthalmopathy | Graves Orbitopathy | Proptosis | IGF1R | Hashimoto

United States, Spain, Italy, United Kingdom, Canada
Horizon Therapeutics USA, Inc.

Completed

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

Thyroid Eye Disease | Chronic (Inactive) Thyroid Eye Disease

United States
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC)

Thyroid Eye Disease | Graves' Orbitopathy

United States, Italy, Germany
Horizon Pharma USA, Inc.

Completed

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X)

Thyroid Eye Disease

Italy, United States, Germany
Horizon Pharma USA, Inc.

Approved for marketing

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease (EAP)

Thyroid Eye Disease | Graves' Orbitopathy

United States
Rebecca Bahn
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

Trial of Rituximab for Graves' Ophthalmopathy

Thyroid-associated Ophthalmopathy

United States
Instituto Nacional de Ciencias Medicas y Nutricion...

Terminated

Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment

Graves Ophthalmopathy

Mexico
University of North Carolina, Chapel Hill

Completed

Reliability of Hertel Exophthalmometer Measurements

Standardization of Hertel Measurements

United States

Search clinical trials for: proptosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations